Furthermore, we revealed that the β-catenin target gene Cyclin D1 is an essential downstream effector that mediates the biological effects of Cyclin K, implying that the Cyclin K/β-catenin/Cyclin D1 pathway represents a potential therapeutic target in lung cancer. This evidence concerns the gene CCND1 and lung carcinoma.